online.liebertpub.com/doi/abs/10.1089/scd.2011.0267
Nov 2, 2011 - ... Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New Therapies. To cite this article: Shengwen Calvin Li, Katherine L. Lee, and Jane Luo. Stem Cells and Development. September 2011, 21(4): 503-506. https://doi.org/10.1089/scd.2011.0267.
Control Dominating Subclones for Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New Therapies
To cite this article:
Shengwen Calvin Li, Katherine L. Lee, and Jane Luo. Stem Cells and Development. September 2011, 21(4): 503-506. https://doi.org/10.1089/scd.2011.0267
Online Ahead of Print: November 2, 2011
Online Ahead of Editing: September 20, 2011
Published in Volume: 21 Issue 4: September 20, 2011
http://online.liebertpub.com/doi/abs/10.1089/scd.2011.0267
Author information
Shengwen Calvin Li,1 Katherine L. Lee,1 and Jane Luo2
1Neuro-Oncology and Stem Cell Research Laboratory, CHOC Children's Hospital Research Institute, University of California Irvine, Orange, California.
2Beckman Coulter, Inc., Brea, California.
Address correspondence to:
Dr. Shengwen Calvin Li
Neuro-Oncology and Stem Cell Research Laboratory
CHOC Children's Hospital Research Institute
University of California Irvine455 South Main Street
Orange, CA 92868
E-mail: shengwel@uci.eduReceived for publication May 26, 2011
Accepted after revision September 20, 2011
ABSTRACT
In contrast to hematological malignancies, meaningful improvements in survival statistics for patients with malignant brain tumors have not been realized in >40 years of clinical research. Clearly, a new medical approach to brain cancers is needed. Recent research has led to a new concept that needs to destroy all cancer subclones to control the cancer progression. However, this new concept fails to distinguish the difference between dominating subclones and dormant subclones. Here, we address the issue of clonal switch and emphasize that there may be one or more than one dominant clones within the tumor mass at any time. Destructing one dominant clone triggers activating other dormant subclones to become dominating subclones, causing cancer progress and post-treatment cancer recurrence. We postulate the concept of subclonal switchboard signaling and the pathway that involved in this process. In the context of stem cell and development, there is a parallel with the concept of quiescent/dormant cancer stem cells (CSC) and their progeny, the differentiated cancer cells; these 2 populations communicate and co-exist. The mechanism with which determines to extend self-renewal and expansion of CSC is needed to elucidate. We suggest eliminating the “dominating subclonal switchboard signals” that shift the dormant subclones to dominating subclones as a new strategy.
This paper was cited by:
Current achievements and future perspectives of metronomic chemotherapy
Adriana Romiti
, Rosa Falcone
, Michela Roberto
, Paolo Marchetti
Investigational New Drugs. Jun 2017, Vol. 35, No. 3: 359-374
Crossref Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?
Nicolas André
, Kelvin Tsai
, Manon Carré
, Eddy Pasquier
Trends in Cancer. May 2017, Vol. 3, No. 5: 319-325
Crossref Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors
Mayuko Furuta
, Masaki Ueno
, Akihiro Fujimoto
, Shinya Hayami
, Satoru Yasukawa
, Fumiyoshi Kojima
, Koji Arihiro
, Yoshiiku Kawakami
, Christopher P. Wardell
, Yuichi Shiraishi
, Hiroko Tanaka
, Kaoru Nakano
, Kazuhiro Maejima
, Aya Sasaki-Oku
, Naoki Tokunaga
, Keith A. Boroevich
, Tetsuo Abe
, Hiroshi Aikata
, Hideki Ohdan
, Kunihito Gotoh
, Michiaki Kubo
, Tatsuhiko Tsunoda
, Satoru Miyano
, Kazuaki Chayama
, Hiroki Yamaue
, Hidewaki Nakagawa
Journal of Hepatology. Feb 2017, Vol. 66, No. 2: 363-373
Crossref The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution
AiLi Chen
, JingYi Yang
, ShaoYan Hu
, Qian-Fei Wang
Science China Life Sciences. Dec 2015, Vol. 58, No. 12: 1302-1305
Crossref Tissue Elasticity Regulated Tumor Gene Expression: Implication for Diagnostic Biomarkers of Primitive Neuroectodermal Tumor
Long T. Vu
, Vic Keschrumrus
, Xi Zhang
, Jiang F. Zhong
, Qingning Su
, Mustafa H. Kabeer
, William G. Loudon
, Shengwen Calvin Li
, Javier S Castresana
PLOS ONE. Mar 2015, Vol. 10, No. 3: e0120336
Crossref Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor
Shengwen Calvin Li
, Lisa May Ling Tachiki
, Mustafa H Kabeer
, Brent A Dethlefs
, Michael J Anthony
, William G Loudon
Cancer Cell International. Dec 2014, Vol. 14, No. 1
Crossref Metronomics: towards personalized chemotherapy?
Nicolas André
, Manon Carré
, Eddy Pasquier
Nature Reviews Clinical Oncology. Jun 2014, Vol. 11, No. 7: 413-431
Crossref Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall
Shengwen Li
, Long T Vu
, Hector W Ho
, Hong Yin
, Vic Keschrumrus
, Qiang Lu
, Jun Wang
, Heying Zhang
, Zhiwei Ma
, Alexander Stover
, John H Weiss
, Philip H Schwartz
, William G Loudon
Cancer Cell International. Jan 2012, Vol. 12, No. 1: 41
Crossref
